Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2018
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic MalignanciesMarina Bacac, Sara Colombetti, Sylvia Herter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2023
Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 BlockadeAnnapaola Mariniello, Tahseen H Nasti, Daniel Y Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2024
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid TumorsSolange Peters, Eric Angevin, Teresa Alonso-Gordoa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2016
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid TumorsMarina Bacac, Tanja Fauti, Johannes Sam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2021
Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor ImmunityEva Sum, Moritz Rapp, Philipp Fröbel, et al.
Nature|September 28, 2022
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cellsLaura Codarri Deak, Valeria Nicolini, Masao Hashimoto, et al.
Molecular Cancer Therapeutics|August 2, 2022
A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of GlioblastomaRaffaella Iurlaro, Inja Waldhauer, Ester Planas-Rigol, et al.
Blood|March 4, 2024
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapyJohannes Sam, Thomas Hofer, Christine Kuettel, et al.
Science Translational Medicine|June 14, 2019
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapyChristina Claus, Claudia Ferrara, Wei Xu, et al.
Pageof 2